Science TLDR

Monday Immune Engager — our weekly pick from the latest immune-engager digest.

Paper: Engineering of acidic pH-responsive anti-CD3 binding antibodies

Authors: Grégory La Sala, Katharina B. Kroell, Mudita Pincha, Christian Gassner, et al.

Journal: mAbs, 2026

Why it matters: Tumor-selective T-cell engagers could dramatically reduce the on-target, off-tumor toxicity that limits current CD3-directed cancer immunotherapies.

Summary

T-cell engagers are bispecific antibodies that physically tether a cytotoxic T-cell to a tumor cell by simultaneously binding a tumor-associated antigen and the CD3 receptor complex — the master activation switch of T-cells. The problem is that CD3-binding potency is indiscriminate: if the target antigen appears even at trace levels on healthy tissue, activated T-cells will attack it. This paper from Roche exploits a well-characterized feature of the tumor microenvironment — a local pH of roughly 6.5–6.8 driven by lactic acid accumulation and poor vascular clearance, versus the tightly regulated systemic pH of 7.4 — to engineer anti-CD3 antibodies that bind avidly inside a tumor but disengage in healthy tissue.

Starting from the parental antibody 40G5C, the team built a phage-display library of hundreds of trillions of sequence variants, selectively incorporating pH-sensitive amino acids (histidine, aspartate, glutamate) at solvent-exposed positions and the CD3 interface. Only 1–2% of recovered clones showed genuine pH-responsive behavior, and the dominant hits were unexpected: threonine-to-aspartate (T89LD) and glutamine-to-glutamate (Q90LE) substitutions in the CDRL3 loop — neither of which directly contacts the CD3 antigen. Constant-pH molecular dynamics (CpHMD) simulations revealed two distinct allosteric mechanisms: Q90LE causes electrostatic rigidification of the CDR binding loops at acidic pH, collapsing into a floppy, non-binding conformation at pH 7.4; T89LD shifts the angle between the variable heavy and light chain domains by approximately 2 degrees at neutral pH, distorting the binding pocket enough to prevent CD3 engagement.

Functional assays in primary human PBMCs confirmed a 789-fold difference in binding affinity between pH 6.5 and pH 7.4 for the Q90LE variant, with corresponding selective T-cell activation (measured by CD69 upregulation). The engineered switch came at a cost to raw potency, but combining Q90LE with affinity-enhancing histidine mutations in the variable domains produced an optimized clone — P1AK5F7-19 — that restored parental-level potency at acidic pH while retaining the safety window at physiological pH.

Three takeaways

Read the paper: https://doi.org/10.1080/19420862.2026.2658902

Paper: Impact of high-power short-duration atrial fibrillation ablation technique on the incidence of silent cerebral embolism: a prospective randomized controlled study

Authors: Wei-Jie Chen, Chun-Xia Gan, Yang-Wei Cai, Yang-Yang Liu, et al.

Journal: BMC Medicine, 2023

Why it matters: Even when catheter ablation successfully restores heart rhythm, microscopic clots can silently lodge in the brain — and this trial tests whether a next-generation cooling catheter actually reduces that hidden risk.

Summary

Catheter ablation for atrial fibrillation (AF) — where radiofrequency energy is used to scar the tissue driving abnormal electrical signals — is highly effective, but the heat applied to actively circulating blood can generate micro-emboli (tiny clots and gaseous particles) that travel to the brain. These "silent cerebral embolisms" (SCEs) produce no immediate symptoms yet show up as new lesions on sensitive imaging in a substantial fraction of patients. This trial asked whether a high-power short-duration (HPSD) strategy, delivering 50 W through a Smart Touch Surround Flow (STSF) catheter — which features 56 circumferential irrigation holes designed to aggressively cool the electrode-tissue interface — reduces SCE incidence compared to the conventional 30–35 W approach using a standard Smart Touch (ST) catheter.

One hundred AF patients were randomized 1:1. High-resolution diffusion-weighted MRI (1 mm slice thickness on a 3.0 T scanner) was performed before and 24–72 hours after ablation to detect new lesions, with cognitive function assessed by the Montreal Cognitive Assessment (MoCA) at baseline, immediately post-procedure, and at three months. The HPSD technique was procedurally faster and required less irrigation fluid, confirming it delivered on its engineering promise. However, SCE rates were nearly identical: 44% in the HPSD group versus 40% in the conventional group (p = 0.685), with no significant differences in lesion count, maximum diameter, or total lesion volume.

Multivariable regression identified persistent AF and a high CHA₂DS₂-VASc score (a validated stroke-risk metric) as the only independent predictors of SCE — not the catheter type or ablation duration. The finding suggests that sluggish, turbulent blood flow in a structurally remodeled, dilated left atrium overwhelms any cooling advantage the hardware provides. Reassuringly, patients who developed SCEs showed no detectable cognitive decline at three months compared to those with clean scans. A key limitation is the relatively small sample of 100 patients, which may have been underpowered to detect modest differences.

Three takeaways

Read the paper: https://doi.org/10.1186/s12916-023-03180-3

Paper: Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP‐43 pathology

Authors: Barış Genç, Mukesh Gautam, Öge Gözütok, Ina Dervishi, Santana Sanchez, et al.

Journal: Clinical and Translational Medicine, 2021

Why it matters: NU-9 is the first compound shown to halt upper motor neuron degeneration — the cortical neurons whose loss defines ALS, primary lateral sclerosis, and hereditary spastic paraplegia — by physically restoring the structural integrity of mitochondria and the endoplasmic reticulum in living animals.

Summary

Upper motor neurons (UMNs), the cortical cells that issue commands for voluntary movement, degenerate in ALS, primary lateral sclerosis (PLS), and hereditary spastic paraplegia (HSP), yet have been largely overlooked in drug development because they are difficult to isolate and monitor in vivo. To address this, the researchers crossed disease mouse models — one driven by misfolded SOD1 protein (mSOD1) toxicity, another by TDP-43 pathology — with a UCHL1-eGFP reporter line that labels UMNs with green fluorescent protein, enabling direct visualization and quantification of these specific neurons during treatment. Electron microscopy revealed that both genetic triggers, despite operating through distinct molecular pathways, converge on the same organelle-level destruction: mitochondria lose their cristae (the inner membrane folds essential for energy production), the endoplasmic reticulum (ER) cisternae fracture and detach from ribosomes, and the apical dendrite — the neuron's primary signal-receiving antenna — becomes riddled with vacuoles. Critically, this pattern of damage was also observed in postmortem tissue from human ALS patients, validating the mouse model at the ultrastructural level.

The compound NU-9, identified from a screen of over 50,000 candidates, was administered orally once daily from postnatal day 60 to day 120 in both disease models. At 100 mg/kg/day, NU-9 demonstrated 94% oral bioavailability, robust blood-brain barrier penetration, and no cardiac or systemic toxicity at therapeutic doses. Electron microscopy at end stage showed near-complete restoration of mitochondrial cristae (healthy mitochondria rising from 10% to 86% of the total pool), reassembly of intact ER cisternae with attached ribosomes, and clearance of apical dendrite vacuoles. UMN counts in treated disease mice matched those of healthy wild-type controls, and treated mice performed significantly better on the hanging wire test. One important caveat: NU-9 had no protective effect on lower motor neurons in the spinal cord, which continued to degenerate at the same rate as in untreated controls — underscoring that upper and lower motor neurons have fundamentally different cellular vulnerabilities.

Three takeaways

Read the paper: https://doi.org/10.1002/ctm2.336

Paper: A trophoblast glycoprotein specific 5T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies

Authors: Milon de Jong, Rok Žiberna, Myrthe Veth, Elisabetta Michielon, et al.

Journal: Clinical Immunology, 2026

Why it matters: Solid tumors have largely resisted bispecific T cell engager therapies due to on-target toxicity in healthy tissue, and this study presents a strategy using gamma-delta T cells that may sidestep that problem.

Summary

Bispecific T cell engagers (bsTCEs) are antibody-like molecules that physically link a tumor antigen to a T cell receptor, forcing immune cells into proximity with cancer cells. While highly effective in blood cancers, their use in solid tumors has been hampered by "on-target off-tumor" toxicity — damage to healthy tissues that express the same antigen being targeted. This study addresses that problem by focusing on two components: the tumor antigen 5T4 (trophoblast glycoprotein), an oncofetal protein broadly overexpressed across solid malignancies but largely absent from healthy adult tissue, and Vγ9Vδ2-T cells, a subset of gamma-delta T cells known for potent anti-tumor activity and an intrinsic capacity to discriminate between stressed tumor cells and normal tissue.

The researchers developed high-affinity VHHs — single-domain antibody fragments derived from camelid antibodies — specific to 5T4, and linked them to a VHH targeting the Vδ2 T cell receptor to create the 5T4-Vδ2 bsTCE. They validated 5T4 expression across a broad panel of solid tumor types and then tested the engager in both conventional 2D cell cultures and more clinically representative 3D patient-derived tumor models. In these systems, the bsTCE triggered robust Vγ9Vδ2-T cell activation, proinflammatory cytokine production, and tumor cell lysis. Critically, when the construct was tested against healthy tissues that do express 5T4 at low levels, Vγ9Vδ2-T cell cytotoxicity was not observed — suggesting that the gamma-delta T cell arm of the engager contributes an intrinsic selectivity that conventional alpha-beta T cell engagers lack. One caveat is that these remain preclinical findings, and whether the tumor-preferential activity holds in the more complex immunosuppressive environment of human tumors in vivo will require clinical investigation.

Three takeaways

Read the paper: https://doi.org/10.1016/j.clim.2026.110707

https://doi.org/10.1038/s41551-025-01569-4

https://doi.org/10.1038/s42256-025-01113-8

https://doi.org/10.1101/2025.06.06.657162

https://doi.org/10.1038/s41586-025-09655-y